Applied DNA Sciences (APDN) News & Sentiment

Applied DNA Sciences, Inc. (NASDAQ:APDN ) Q1 2025 Earnings Conference Call February 13, 2025 4:30 PM ET Company Participants Sanjay Hurry - Executive Director, IR & Corporate Communications Beth Jantzen - CFO James Hayward - Chairman & CEO Clay Shorrock - Chief Legal Officer & Executive Director, Business Development Judith Murrah - President & Secretary Conference Call Participants Eduardo Arce - H.C. Wainwright & Co Operator Good day, and welcome to the Applied DNA Sciences First Quarter Fiscal 2025 Financial Results.

Applied DNA Sciences (APDN) came out with a quarterly loss of $0.56 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $1.80 per share a year ago.

Applied DNA Sciences (APDN) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $5.20 per share a year ago.

Is the next pandemic here. With health officials declaring Monkeypox a public health emergency, investors need to be watching Monkeypox-related stocks.

Applied DNA Sciences, Inc. (NASDAQ:APDN ) Q3 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Corporate Participants Sanjay Hurry - Head of IR Beth Jantzen - Chief Financial Officer Jim Hayward - Chairman, President and Chief Executive Officer Clay Shorrock - Chief Legal Officer and Head of Business Development Conference Call Participants Operator Good day, and welcome to the Applied DNA Fiscal Third Quarter 2024 Investor Conference Call. All participants will be listen-only mode.

Applied DNA Sciences (APDN) came out with quarterly earnings of $0.47 per share, beating the Zacks Consensus Estimate of a loss of $0.64 per share. This compares to loss of $4.80 per share a year ago.

Applied DNA Sciences (APDN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

STONY BROOK, NY / ACCESSWIRE / May 13, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA) and the Institute of Hematology and Blood Transfusion (ÚHKT/IHBT) have announced that an abstract on the development of an enzymatic, non-viral manufacturing workflow for efficient production of clinical-grade CAR T-cell therapies has been accepted for presentation at the European Hematology Association 2024 Hybrid Congress in Madrid, Spain from June 13 - 16, 2024. The accepted abstracts will be available on the Congress' website from May 14, 2024.

Here is how Applied DNA Sciences (APDN) and Encore Wire (WIRE) have performed compared to their sector so far this year.